Inusiran (AK102)
Hypercholesterolemia
ApprovedCommercial
Key Facts
About Akeso
Founded in 2012, Akeso has established itself as a cornerstone of China's biopharmaceutical innovation, with a mission to develop world-class, first-in-class and best-in-class therapies. Its achievements include the global firsts of PD-1/CTLA-4 (cadonilimab) and PD-1/VEGF (ivonescimab) bispecific antibodies, a landmark $5B+ out-licensing deal, and FDA approval for its PD-1 inhibitor. The company's strategy leverages its integrated ACE Platform for end-to-end drug development, aggressive global partnerships, and a diversified pipeline spanning oncology, autoimmunity, and metabolic diseases to drive sustainable growth.
View full company profileTherapeutic Areas
Other Hypercholesterolemia Drugs
| Drug | Company | Phase |
|---|---|---|
| VXX-401 | Vaxxinity | Phase 1 |
| Atorvastatin Oral Liquid Suspension | CMP Pharma | Approved |
| AFFITOPE® AT04 (licensed to Frontier Biotech) | AFFiRiS | Phase 1 |
| AQR-008 | Aqur Biosciences | Pre-clinical |
| Leqvio® (inclisiran) | Novartis | Approved |
| MK-0616 | Merck | Phase 3 |
| SHR-1209 | Jiangsu Hengrui Medicine | Phase III |
| IBI-306 | Innovent Biologics | NDA Submitted |
| Obicetrapib + Ezetimibe FDC | NewAmsterdam Pharma Company | Phase 3 |